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The innate immune response to malaria is a major determinant of disease severity and outcome. In this issue
of Immunity, Sharma et al. (2011) provide evidence of a unique DNA sensing pathway that may contribute to
immunopathology in plasmodial infections.Plasmodium species, the causative
agents of malaria, are unicellular eukary-
otic parasites with complex life cycles.
Symptomatic malaria occurs during para-
site replication in host erythrocytes.
Although most infections are uncompli-
cated and resolve with prompt antipara-
sitic treatment, 1%–2% of Plasmodium
falciparum infections progress to severe
malaria, a heterogeneous array of life-
threatening syndromes. Notable among
these is cerebral malaria (CM), which is
characterized by coma and has a 20%
case fatality rate despite optimal antima-
larial therapy. The pathogenesis of CM re-
mains incompletely understood. Autopsy
findings include cerebral edema, brain
hemorrhages, axonal damage, and
accumulation of parasitized erythrocytes
in cerebral vessels. Cerebral parasite
‘‘sequestration’’ is believed to promote
CM by damaging endothelial cells and
compromising perfusion. However, there
is also compelling evidence that the host
response plays an important role in the
pathogenesis and outcome of CM (van
der Heyde et al., 2006). CM is associated
with high levels of proinflammatory cyto-
kines both systemically and in the brain,
and this is thought to promote parasite
sequestration and vascular leak by acti-
vating endothelium and may directly
impair neuronal function.
Understanding how malaria triggers
deleterious host responses may enable
development of novel adjunctive thera-
pies to improve outcome for CM. Innate
immune pathways have been interro-
gated, given that severe disease most
commonly occurs in individuals with little
to no immunity. TLRs and NLRs have
been found to mediate inflammatory
responses to malaria (Figure 1), although
in vitro findings are not always borne out
in vivo. For example, P. falciparum glyco-
sylphosphatidylinositols activate Toll-likereceptor 2 (TLR2) in vitro, but TLR2 defi-
ciency did not affect disease outcome in
murine malaria models. TLR9 has been
consistently implicated in malaria patho-
genesis in vivo, but its ligand is controver-
sial. Hemozoin, an insoluble heme poly-
mer generated by the parasite upon
hemoglobin degradation, was found to
directly stimulate TLR9 by some (Coban
et al., 2005), whereas others contend
that TLR9 recognizes parasite DNA traf-
ficked into endosomes by hemozoin or
parasite proteins (Parroche et al., 2007;
Wu et al., 2010).
Most studies have examined innate
immune pathways that generate proin-
flammatory cytokines implicated in CM
pathogenesis. In contrast, little is known
about the role of type I interferons (IFNs)
in malaria infection. Although traditionally
regarded as antiviral cytokines, type I
IFNs can modulate host defense in a
variety of ways. Type I IFNs can prime
macrophage proinflammatory responses
and intracellular killing; enhance dendritic
cell (DC) maturation and T helper 1 (Th1)
cell responses; promote lymphocyte
activity; and, in some contexts, dampen
inflammation. Plasmodium parasites in-
duce type I IFNs in vitro, but themechanics
and significance of this response are
poorly defined. Limited human data
suggest associations between type I IFN
pathways and malaria severity (Luty
et al., 2000). In a murine model of ex-
perimental CM (ECM) caused by the
Plasmodium berghei ANKA (PbA) strain,
type I IFN-related geneswere upregulated
in the brains of susceptible versus resis-
tant mice (Lovegrove et al., 2007).
In this issue of Immunity, Sharma et al.
(2011) identify a Plasmodium pathogen-
associated molecular pattern (PAMP),
AT-rich DNA, which stimulates type I IFN
production via a unique pathway, and
demonstrate a pathogenic role for type IImmunity 35IFNs in the ECM model. They first con-
firmed that P. falciparum induced IFN-b
in vitro and showed that Type I inter-
feron-stimulated genes were upregulated
in leukocytes from P. falciparum-infected
patients. The basis for these responses
was then investigated. Parasite DNA
was proposed as the candidate PAMP,
given the propensity of nucleic acids to
stimulate type I IFNs. Paralleling their
previous report that hemozoin delivers
parasite DNA to the endosome for TLR9
recognition (Parroche et al., 2007), they
found that hemozoin purified from
P. falciparum cultures induced IFN-b,
and this effect was abolished with DNase
treatment. IFN-b responses to trans-
fected P. falciparum genomic DNA were
TLR9 independent and were triggered in
the cytosol. Immunofluorescence data
showed dissociation of hemozoin and
lysosomes at late time points, suggesting
that internalized hemozoin impaired
phagolysosomal integrity and thus al-
lowed parasite DNA access to the cyto-
sol. However, there is disagreement in
the field regarding phagolysosomal dis-
ruption by hemozoin (Shio et al., 2009),
as well as hemozoin-DNA association
more generally (Wu et al., 2010). The use
of more refined techniques will be critical
to verify this mechanism.
Although CpG motifs in pathogen DNA
are best studied for their immunostimula-
tory activity, an AT-rich motif has been
found to trigger innate responses via
TLR9 (Shimosato et al., 2006). The
P. falciparum genome, which has 80%
AT content, was found to contain >6,000
copies of this motif. Oligonucleotides
(ODNs) based on P. falciparum se-
quences containing the AT-rich motif
were generated. Cytosol-targeted ODN
transfection induced type I IFNs and
proinflammatory cytokines in a variety of
human and mouse cells. With a structural, August 26, 2011 ª2011 Elsevier Inc. 149
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Figure 1. Recognition of AT-Rich Plasmodium DNA by a Unique Cytosolic Sensing Pathway
PlasmodiumDNAmay gain access to the cytosol because of disruption of phagolysosomal integrity by the
parasite-generated crystal hemozoin. AT-rich motifs in the parasite genome are detected by an unknown
cytosolic receptor, which couples to STING and TBK1 to stimulate IRF3 and IRF7-dependent type I IFN
production. This pathway is shown in the context of the current understanding of innate immune recogni-
tion of Plasmodium. Further investigation is required to determine the relative importance and interactions
between these pathways during human malaria infection and whether they can be manipulated for
therapeutic benefit.
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Previewsprediction algorithm and mutant ODNs, it
was found that a stem-loop secondary
structure was critical for ODN activity.
For determining how AT-rich ODNs
induced IFN-b, all innate sensors known
to induce type I IFNs were systematically
evaluated. TLRs, Nod2, DAI, and IFI16/
p204 were dispensable for IFN-b re-
sponses, aswas theRNAPIII-RIG-I-depen-
dentmechanism thatmediates recognition
of poly(dA-dT) DNA. Nevertheless, a
number of key signaling components
were identified (Figure 1). ER-associated
protein stimulator of IFN genes (STING)
and Tank-binding kinase-1 (TBK1) formed
a physical complex with transfected
ODNs and were critical for IFN-b produc-
tion. TBK1-activated transcription factors150 Immunity 35, August 26, 2011 ª2011 ElsIRF3 and IRF7 were also essential. Impor-
tantly, these in vitro findings were then
extended to more biologically relevant
models. The implicated signaling effectors
were confirmed to be required for IFN-b
responses to P. falciparum genomic DNA
and P. falciparum- and PbA-parasitized
erythrocytes, although STINGonly partially
mediated responses to parasitized eryth-
rocytes. Furthermore, mice deficient in
TBK1, IRF3, and IRF7, or type I IFN
receptor IFNabR, were protected from the
ECM syndrome and death during PbA
infection, suggesting the importance of
this recognition pathway in vivo.
These intriguing findings raise many
new questions. Does Plasmodium ge-
nomic DNA require specific processingevier Inc.by cellular DNases to form the requisite
stem-loop structures? How does this
pathway interact with other innate im-
mune pathways? And, critically, what is
the cytosolic innate immune sensor for
AT-rich DNA? siRNA screening or mass
spectrometric analysis of ODN pull-
down assaysmay help reveal this mystery
receptor. This would facilitate further
investigation of this pathway in malaria,
given that the downstream signaling
mediators identified in this work are
involved in multiple type I IFN-inducing
pathways. Indeed, it remains to be for-
mally proven that the type I IFN-mediated
pathology in ECM was attributable to
recognition of AT-rich Plasmodium DNA
rather than another Plasmodium or host
component (particularly because STING-
deficient mice were not evaluated).
The relevance of these findings to hu-
man malaria infection is currently unclear.
Human malaria species P. falciparum
and Plasmodium vivax possess similar
numbers of immunostimulatory AT-rich
motifs in their genomes, despite the
greater virulence of P. falciparum. This
defies straightforward correlation be-
tween the abundance of these motifs
and malaria severity. It is possible that
AT-rich motifs are differently accessible
in P. falciparum and P. vivax infections or
that the lower parasite burdens in
P. vivax infection prevent extensive acti-
vation of this pathway. Comparison of
plasma type I IFN amounts in malaria
patients and ex vivo IFN responses to
parasite isolates would be informative.
The implication of type I IFNs in ECM
pathogenesis is an important advance.
However, it should be noted that this
model does not perfectly replicate human
CM. Elucidating the basis of protection of
IFNabR-deficient mice (e.g., reduced
parasite accumulation in the brain?
Reduced cytokine levels?) is critical for
assessing the significance of this finding.
Given the ability of type I IFNs to promote
proinflammatory responses and the
involvement of such responses in ECM
pathogenesis, this is a highly plausible
mechanism. However, the role of inflam-
mation in severe malaria pathogenesis is
multifaceted, which precludes broad
conclusions regarding specificmediators.
Human and murine data suggest that
although excessive inflammation can be
detrimental, early robust proinflammatory
responses limit parasite replication and
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consistent with the finding that recombi-
nant IFN-a administration early in PbA
infection reduced parasitemia and pro-
tected against ECM in a IFN-g-dependent
manner (Vigario et al., 2007). A beneficial
effect of type I IFNs was also suggested
by higher plasma IFN-a levels in African
children with mild malaria compared to
those with hyperparasitemia or severe
malarial anemia (Luty et al., 2000). The
heterogeneity and complexity of human
severe malaria necessitate examining
the role of type I IFNs in diverse patient
populations and in multiple murine
models representing different aspects of
human disease. However, the present
findings do caution against administration
of type I IFNs as adjunctive therapy for
CM, especially because patients typically
present with advanced pathology.
In summary, Sharma et al. (2011)
identify a unique cytosolic DNA sensing
pathway and considerably expand our
knowledge of the induction and role oftype I IFNs in malaria infection. The pres-
ence of AT-rich motifs in the genomes of
other protozoa, bacteria, and humans
suggests that these motifs could con-
tribute to the pathogenesis of other
severe infectious syndromes. In the case
of extracellular DNA sources, it is in-
triguing to consider that other crystals
(e.g., urate) may move these motifs into
the cytosol for innate sensing. This pro-
posed mechanism, if confirmed, may
have relevance for the development of
DNA-based vaccine adjuvants.REFERENCES
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In the current issue of Immunity, Martı´nez-Martı´n et al. (2011) describe the central supramolecular activation
cluster (cSMAC) as a site of clathrin-independent T cell receptor (TCR) internalization and trogocytosis.
Further, they identify small Rho GTPases TC21 and RhoG as key mediators of these processes.Cell-to-cell communication is essential for
the orchestration of the immune system
and its responses. Although immune cells
normally communicate through either
soluble or membrane-bound mediators,
new types of cellular interchange have
been described, including trogocytosis,
exosome secretion, and nanotube forma-
tion. The term trogocytosis (from Greek
trogo-, nibble) was originally coined to
describe the intercellular transfer of
membrane patches from an antigen-pre-senting cell (APC) to a lymphocyte (Joly
and Hudrisier, 2003). This is in strong
contrast to phagocytosis, the process of
engulfing whole pathogens and death
cell fragments by phagocytes.
The first evidence of trogocytosis was
the transfer of major histocompatibility
complex class II (MHCII) glycoproteins
from B to T cells (Cone et al., 1972). Since
then, trogocytotic activity has been re-
ported for T, B, natural killer (NK), and
dendritic cells and is well documentedin vitro and in vivo. Trogocytosis can be
distinguished from other mechanisms of
intercellular transfer because it requires
close cell-cell contact, is quick (within
minutes), and involves transfer of intact
proteins. Previous studies focused on the
cell types involvedand themolecules trans-
ferred, but the molecular mechanism that
underpins this phenomenon has remained
largely unknown. Trogocytosis is an active
process in T and NK cells, requiring both
receptor signaling and actin cytoskeleton, August 26, 2011 ª2011 Elsevier Inc. 151
